Close Menu

NEW YORK (GenomeWeb) – The American Society of Clinical Oncology published revised early-stage breast cancer guidelines today that feature a focused update recommending Agendia's MammaPrint for guiding treatment decisions in early stage breast cancer patients with 1-to-3 positive lymph nodes.

According to the company, the revision is the fourth this year regarding MammaPrint, and is supported by data from the randomized, prospective, Phase III MINDACT trial, which was published last year.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Jul
23

This webinar will discuss how the Molecular Pathology Laboratory at the University of Oklahoma (OUMP) is using a new quality improvement model to support molecular testing of oncology patients.